Clinical Trial Update: Cobimetinib for BRAF-wild-type or Mutated Histiocytoses [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating cobimetinib for histiocytoses (BRAF-wild-type or mutated) has completed. The update does not provide trial results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Histiocytosis

Drugs mentioned

• Cotellic (cobimetinib)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Disease or R Group Histiocytoses | Phase 3 | Status: COMPLETED